Shin Nippon Biomedical Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Shin Nippon Biomedical Laboratories has a total shareholder equity of ¥36.5B and total debt of ¥35.0B, which brings its debt-to-equity ratio to 95.9%. Its total assets and total liabilities are ¥89.0B and ¥52.5B respectively. Shin Nippon Biomedical Laboratories's EBIT is ¥1.9B making its interest coverage ratio 59.1. It has cash and short-term investments of ¥11.2B.
Key information
95.9%
Debt to equity ratio
JP¥34.96b
Debt
| Interest coverage ratio | 59.1x |
| Cash | JP¥11.21b |
| Equity | JP¥36.45b |
| Total liabilities | JP¥52.53b |
| Total assets | JP¥88.98b |
Recent financial health updates
No updates
Recent updates
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Sep 19
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts
Aug 09Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding
Aug 06Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 26Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00
Jul 12Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 21Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 10Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00
Mar 12Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00
Feb 27Financial Position Analysis
Short Term Liabilities: 2395's short term assets (¥34.0B) exceed its short term liabilities (¥28.8B).
Long Term Liabilities: 2395's short term assets (¥34.0B) exceed its long term liabilities (¥23.7B).
Debt to Equity History and Analysis
Debt Level: 2395's net debt to equity ratio (65.2%) is considered high.
Reducing Debt: 2395's debt to equity ratio has increased from 67% to 95.9% over the past 5 years.
Debt Coverage: 2395's debt is not well covered by operating cash flow (4.7%).
Interest Coverage: 2395's interest payments on its debt are well covered by EBIT (59.1x coverage).